The Prevalence of Immediate Hypersensitivity Reactions to the BNT162b2 mRNA Vaccine against SARS-CoV-2: Data from the Vaccination Campaign in a Large Academic Hospital

The anti-SARS-CoV-2 vaccination has probably been the most effective tool for preventing the infection and negative outcomes of the COVID-19 disease, and therefore for interrupting the pandemic state. The first licensed SARS-CoV-2 vaccine was BNT162b2, an mRNA vaccine that has been widely used since...

Descripción completa

Detalles Bibliográficos
Autores principales: Paoletti, Giovanni, Pepys, Jack, Bragato, Maria Chiara, Paoletti, Sandro, Piona, Alessandra, Messina, Maria Rita, Racca, Francesca, Ferri, Sebastian, Nappi, Emanuele, Costanzo, Giovanni, Del Moro, Lorenzo, Puggioni, Francesca, Canonica, Giorgio Walter, Azzolini, Elena, Heffler, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223765/
https://www.ncbi.nlm.nih.gov/pubmed/37243007
http://dx.doi.org/10.3390/vaccines11050903

Ejemplares similares

Ejemplares similares